Luminosity Consulting is proud to announce a strategic collaboration with Biogenes, a biotechnology leader pioneering the development of aptamer-based diagnostics and therapeutics. This partnership marks a significant step in advancing global healthcare solutions that are sustainable, scalable, and accessible.

​​

Headquartered in Malaysia, Biogenes has developed a proprietary end-to-end platform for creating aptamers — synthetic, DNA-based alternatives to traditional animal-derived antibodies. These advanced molecules can be designed and developed using software, enabling faster development cycles, greater reproducibility, and improved cost-efficiency compared to conventional antibody production.

With more than 400 aptamers developed, 30+ products launched, and two already integrated into diagnostics in Southeast Asia, Biogenes is rapidly emerging as one of Southeast Asia’s most impactful biotech firms.

​​

Driving Strategic UK Expansion​

​

Luminosity will work closely with Biogenes on its UK repositioning strategy, including the establishment of Biogenes UK as the company’s global headquarters and asset-holding entity. This move will leverage the UK’s strengths in biotech innovation, funding access, and regulatory expertise — opening new markets across the UK, EU, and Africa while maintaining strong commercial momentum in Southeast Asia.

​​

Our role also includes advising Biogenes on a major investment round designed to fuel the next phase of its growth. This funding will support expansion of the diagnostics pipeline, therapeutic development, IP consolidation, and go-to-market execution.

 

“Aptamers represent a paradigm shift in how we approach diagnostics and therapeutics — they are faster to develop, more cost-effective, and ethically superior to traditional antibodies,” said Adrian Joseph, CEO of Biogenes. “With Luminosity’s strategic insight and global network, we are well-positioned to bring this technology to the world stage.”

​​

“At Luminosity, we work with companies whose innovations have the power to transform industries and improve lives,” said Sangeeta Sachi, Director at Luminosity Consulting. “Biogenes is exactly that — a mission-driven company with the science, infrastructure, and vision to make an extraordinary global impact.”

​​

About the Technology

​

​The global antibody market, valued at over £200 billion, is dependent on animal-derived antibodies — an approach that is costly, unstable, and ethically challenging. Biogenes’ aptamer technology offers a sustainable, animal-free alternative, with unmatched scalability, stability, and precision. The company operates from a 10,000 sq ft R&D lab and a 10,000 sq ft ISO 13485-certified manufacturing facility, ensuring full control over product innovation and quality.

​

This collaboration reflects Luminosity Consulting’s commitment to advancing high-impact innovations with the potential to reshape industries and deliver measurable benefits to society.